

RECEIVED  
CENTRAL FAX CENTER

In The Claims:

APR 02 2008

Original Claims 1-24 are currently pending in this application. Claims 1, 5, 9, 13 and 21 are amended without prejudice or disclaimer of the subject matter therein.

1. (Currently Amended) A method for preventing or treating PAN-drug-induced nephrotoxicity in an individual, comprising: administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.
2. (Original) The method of claim 1, wherein said estradiol metabolite is selected from the group consisting of 2-hydroxyestradiol, 2-methoxyestradiol, 4-hydroxyestradiol and 4-methoxyestradiol.
3. (Original) The method of claim 1, wherein said composition comprises a controlled release formulation of said composition.
4. (Original) The method of claim 1, wherein said composition comprises a prodrug of said estradiol metabolite.
5. (Currently Amended) A method for preventing or treating PAN-drug-induced proteinuria in an individual, comprising: administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.
6. (Original) The method of claim 5, wherein said estradiol metabolite is selected from the group consisting of 2-hydroxyestradiol, 2-methoxyestradiol, 4-hydroxyestradiol and 4-methoxyestradiol.
7. (Original) The method of claim 5, wherein said composition comprises a controlled release formulation of said composition.
8. (Original) The method of claim 5, wherein said composition comprises a prodrug of said estradiol metabolite.

9. (Currently Amended) A method for preventing or treating PAN-drug-induced decreases in glomerular filtration rate in an individual, comprising: administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.

10. (Original) The method of claim 9, wherein said estradiol metabolite is selected from the group consisting of 2-hydroxyestradiol, 2-methoxyestradiol, 4-hydroxyestradiol and 4-methoxyestradiol.

11. (Original) The method of claim 9, wherein said composition comprises a controlled release formulation of said composition.

12. (Original) The method of claim 9, wherein said composition comprises a prodrug of said estradiol metabolite.

13. (Currently Amended) A method for preventing or treating PAN-drug-induced infiltration of inflammatory cells into renal tissue in an individual, comprising: administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.

14. (Original) The method of claim 13, wherein said estradiol metabolite is selected from the group consisting of 2-hydroxyestradiol, 2-methoxyestradiol, 4-hydroxyestradiol and 4-methoxyestradiol.

15. (Original) The method of claim 13, wherein said composition comprises a controlled release formulation of said composition.

16. (Original) The method of claim 13, wherein said composition comprises a prodrug of said estradiol metabolite.

17. (Original) A method for preventing or treating drug-induced excessive proliferation of renal cells in an individual, comprising: administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.

18. (Original) The method of claim 17, wherein said estradiol metabolite is selected from the group consisting of 2-hydroxyestradiol, 2-methoxyestradiol, 4-hydroxyestradiol and 4-methoxyestradiol.

19. ((Original) The method of claim 17, wherein said composition comprises a controlled release formulation of said composition.

20. (Original) The method of claim 17, wherein said composition comprises a prodrug of said estradiol metabolite.

21. (Currently Amended) A method for preventing or treating PAN-drug-induced excessive extracellular matrix protein production in renal tissue in an individual, comprising: administering to said individual a therapeutically effective amount of a composition comprising an estradiol metabolite.

22. (Original) The method of claim 21, wherein said estradiol metabolite is selected from the group consisting of 2-hydroxyestradiol, 2-methoxyestradiol, 4-hydroxyestradiol and 4-methoxyestradiol.

23. (Original) The method of claim 21, wherein said composition comprises a controlled release formulation of said composition.

24. (Original) The method of claim 21, wherein said composition comprises a prodrug of said estradiol metabolite.